ANG Lifesciences

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE236W01016
  • NSEID:
  • BSEID: 540694
INR
37.23
-0.26 (-0.69%)
BSENSE

Nov 20

BSE+NSE Vol: 5.47 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
{
  "main_header": {
    "sid": 1002820,
    "name": "ANG Lifesciences",
    "stock_name": "ANG Lifesciences",
    "full_name": "ANG Lifesciences India Ltd",
    "name_url": "stocks-analysis/ang-lifesciences",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "37.23",
    "chg": -0.26,
    "chgp": "-0.69%",
    "dir": -1,
    "prev_price": "37.49",
    "mcapval": "49.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540694,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE236W01016",
    "curr_date": "Nov 20",
    "curr_time": "",
    "bse_nse_vol": "5.47 k",
    "exc_status": "Active",
    "traded_date": "Nov 20, 2026",
    "traded_date_str": "2026 11 20",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/ang-lifesciences-1002820-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "ANG Lifesciences India Ltd Downgraded to Strong Sell Amid Weak Financials and Mixed Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/ang-lifesciences-india-ltd-downgraded-to-strong-sell-amid-weak-financials-and-mixed-technicals-4238454",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ANGLifesciences_mojoScore_4238454.png",
        "date": "2026-10-26 08:21:19",
        "description": "ANG Lifesciences India Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 23 Oct 2026, reflecting deteriorating financial fundamentals and a complex technical outlook. Despite some mildly bullish technical signals, the company’s weak profitability, high debt burden, and negative operating performance have weighed heavily on investor sentiment, leading to a significant reassessment of its prospects."
      },
      {
        "title": "ANG Lifesciences India Ltd Upgraded to Sell Amid Mixed Technical and Financial Signals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/ang-lifesciences-india-ltd-upgraded-to-sell-amid-mixed-technical-and-financial-signals-4233128",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ANGLifesciences_mojoScore_4233128.png",
        "date": "2026-10-22 08:41:24",
        "description": "ANG Lifesciences India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 21 Oct 2026, driven primarily by improved technical indicators despite ongoing financial challenges. The micro-cap pharmaceutical company’s Mojo Score rose to 31.0, reflecting a shift in market sentiment, although fundamental weaknesses and valuation concerns persist."
      },
      {
        "title": "ANG Lifesciences India Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/ang-lifesciences-india-ltd-is-rated-strong-sell-4231659",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ANGLifesciences_mojoScore_4231659.png",
        "date": "2026-10-21 10:10:56",
        "description": "ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 21 October 2026, providing investors with the latest comprehensive view."
      },
      {
        "title": "ANG Lifesciences India Ltd is Rated Strong Sell",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/ang-lifesciences-india-ltd-is-rated-strong-sell-4216021",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/10/ANGLifesciences_mojoScore_4216021.png",
        "date": "2026-10-06 10:11:00",
        "description": "ANG Lifesciences India Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 22 September 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed here are current as of 06 October 2026, providing investors with the latest perspective on the company’s position."
      },
      {
        "title": "ANG Lifesciences India Ltd Downgraded to Strong Sell Amid Weak Financials and Mixed Technicals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/ang-lifesciences-india-ltd-downgraded-to-strong-sell-amid-weak-financials-and-mixed-technicals-4201891",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ANGLifesciences_mojoScore_4201891.png",
        "date": "2026-09-23 08:21:50",
        "description": "ANG Lifesciences India Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 22 September 2026, reflecting a complex interplay of deteriorating financial fundamentals and mixed technical signals. Despite some positive price momentum over recent months, the company’s weak profitability, high leverage, and subdued long-term prospects have compelled analysts to revise their stance, signalling caution for investors in this micro-cap pharmaceutical stock."
      },
      {
        "title": "ANG Lifesciences India Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals",
        "link": "https://researchintel.adityabirlamoney.com/news/stock-recommendation/ang-lifesciences-india-ltd-upgraded-to-sell-on-technical-improvements-despite-weak-fundamentals-4196866",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/ANGLifesciences_mojoScore_4196866.png",
        "date": "2026-09-18 08:15:20",
        "description": "ANG Lifesciences India Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 17 Sep 2026, driven primarily by improved technical indicators. However, the company’s financial health and valuation metrics remain weak, reflecting ongoing operational challenges and elevated risk for investors."
      }
    ],
    "total": 25,
    "sid": "1002820",
    "stock_news_url": "https://researchintel.adityabirlamoney.com/news/ang-lifesciences-india-1002820"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "18-Nov-2026",
      "details": "Cessation of Independent Director upon completion of tenure.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "14-Nov-2026",
      "details": "Appointment of Mrs. Preeti Sarin as Additional Independent Director of the Company",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter And Half Year Ended 30.09.2026.",
      "datetime": "14-Nov-2026",
      "details": "Financial Results for the quarter and half year ended 30.09.2026.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "ANG Lifesciences India Ltd has declared <strong>10%</strong> dividend, ex-date: 02 Nov 21",
          "dt": "2021-11-02",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "ANG Lifesciences India Ltd has announced <strong>1:4</strong> bonus issue, ex-date: 13 Jul 22",
          "dt": "2022-07-13",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}
stock newsNews and Views
stock-recommendationAnnouncement

Announcement under Regulation 30 (LODR)-Change in Management

18-Nov-2026 | Source : BSE

Cessation of Independent Director upon completion of tenure.

Announcement under Regulation 30 (LODR)-Change in Management

14-Nov-2026 | Source : BSE

Appointment of Mrs. Preeti Sarin as Additional Independent Director of the Company

Financial Results For The Quarter And Half Year Ended 30.09.2026.

14-Nov-2026 | Source : BSE

Financial Results for the quarter and half year ended 30.09.2026.

stock-recommendationCorporate Actions
Corporate Actions
info
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

ANG Lifesciences India Ltd has declared 10% dividend, ex-date: 02 Nov 21

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

ANG Lifesciences India Ltd has announced 1:4 bonus issue, ex-date: 13 Jul 22

stock-summary
RIGHTS

No Rights history available